I thought WSU already did a pre-clinical trial establishing those things (preservation of oligodendrocytes, etc) for 2-73 and DM? Were they talking (in your post) about the need for future clinical trials to confirm what they found pre-clinically? Or, is it a case that WSU found that 2-73 and DM did impress pre-clinically, they now want to find out what aspect of their MOA's (sigma 1, NMDA, muscarinic) is/are responsible for the positive results?